These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 31644555)

  • 21. Influence of preoperative anti-HLA antibodies on short- and long-term graft survival in recipients with or without rituximab treatment.
    Ishida H; Furusawa M; Shimizu T; Nozaki T; Tanabe K
    Transpl Int; 2014 Apr; 27(4):371-82. PubMed ID: 24438437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience.
    Shirakawa H; Ishida H; Shimizu T; Omoto K; Iida S; Toki D; Tanabe K
    Clin Transplant; 2011; 25(6):878-84. PubMed ID: 21175849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.
    Sinangil A; Ucar ZA; Koc Y; Barlas S; Abouzahir S; Ecder ST; Akin EB
    Transplant Proc; 2019 Sep; 51(7):2268-2273. PubMed ID: 31358450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness and safety of rituximab as induction therapy in ABO-compatible non-sensitized renal transplantation: a systematic review and meta-analysis of randomized controlled trials.
    Cheungpasitporn W; Thongprayoon C; Edmonds PJ; Bruminhent J; Tangdhanakanond K
    Ren Fail; 2015; 37(9):1522-6. PubMed ID: 26337918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment.
    Nordén G; Briggs D; Cockwell P; Lipkin G; Mjörnstedt L; Mölne J; Ready A; Rydberg L; Samuelsson O; Svalander CT; Breimer ME
    Xenotransplantation; 2006 Mar; 13(2):148-53. PubMed ID: 16623810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption.
    Becker LE; Siebert D; Süsal C; Opelz G; Leo A; Waldherr R; Macher-Goeppinger S; Schemmer P; Schaefer SM; Klein K; Beimler J; Zeier M; Schwenger V; Morath C
    Transplantation; 2015 Nov; 99(11):2364-71. PubMed ID: 25989497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of rituximab dosage for ABO-incompatible living-donor kidney transplantation.
    Nakao T; Ushigome H; Kawai K; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Yoshimura N
    Transplant Proc; 2015 Apr; 47(3):644-8. PubMed ID: 25891703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Different Rituximab Doses on B Cell Count, Anti-A/B Antibody Titer, Graft Function, and Infectious Complications in ABO-Incompatible Renal Transplantation: A Prospective Study.
    Thukral S; Shinde N; Ray DS
    Transplant Proc; 2021 Apr; 53(3):970-975. PubMed ID: 33279260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers.
    Opelz G; Morath C; Süsal C; Tran TH; Zeier M; Döhler B
    Transplantation; 2015 Feb; 99(2):400-4. PubMed ID: 25050471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tailored immunosuppression after kidney transplantation - a single center real-life experience.
    Good-Weber M; Roos M; Mueller TF; Rüsi B; Fehr T
    BMC Nephrol; 2020 Nov; 21(1):501. PubMed ID: 33228545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens.
    Tanabe K; Ishida H; Shimizu T; Omoto K; Shirakawa H; Tokumoto T
    Contrib Nephrol; 2009; 162():61-74. PubMed ID: 19001814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
    De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
    Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
    Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
    Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood group O recipients associated with early graft deterioration in living ABO-incompatible kidney transplantation.
    Toki D; Ishida H; Horita S; Yamaguchi Y; Tanabe K
    Transplantation; 2009 Nov; 88(10):1186-93. PubMed ID: 19935372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose Thymoglobulin vs Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: A Prospective Randomized Trial.
    Martinez-Mier G; Moreno-Ley PI; Budar-Fernández LF; Méndez-López MT; Allende-Castellanos CA; Jiménez-López LA; Barrera-Amoros DA; Aguilar-Sandoval E; De la Paz-Román M; Soto-Miranda E; Rivera-Sanchez Y; Martínez-Maldonado M
    Transplant Proc; 2021 Apr; 53(3):1005-1009. PubMed ID: 32178925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors.
    Gloor JM; Lager DJ; Moore SB; Pineda AA; Fidler ME; Larson TS; Grande JP; Schwab TR; Griffin MD; Prieto M; Nyberg SL; Velosa JA; Textor SC; Platt JL; Stegall MD
    Transplantation; 2003 Apr; 75(7):971-7. PubMed ID: 12698082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful launch of an ABO-incompatible kidney transplantation program to overcome the shortage of compatible living donors: experience at a single center
.
    Song SH; Lee J; Kim BS; Kim S; Lee JG; Jeong HJ; Kim YS; Kim MS; Kim HO; Kim SI; Huh KH
    Clin Nephrol; 2017 Sep; 88(9):117-123. PubMed ID: 28679466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ABO-incompatible renal transplantation at Tokyo Women's Medical University.
    Tanabe K; Tokumoto T; Ishida H; Toma H; Nakajima I; Fuchinoue S; Teraoka S
    Clin Transpl; 2003; ():175-81. PubMed ID: 15387109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High B-cell activating factor is not associated with worse 3-year graft outcome in blood group-incompatible kidney transplantation with rituximab induction.
    Lehnhardt AM; Strecker M; Eiermann T; Marget M; Thaiss F; Nashan B; Koch M
    Clin Transplant; 2015 Apr; 29(4):359-64. PubMed ID: 25627801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.